Navigation Links
EntreMed Receives NASDAQ Listing Rule 5550(b)(2) Determination Letter
Date:8/19/2010

ROCKVILLE, Md., Aug. 19 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced that it has received a NASDAQ Staff Determination Letter indicating that the Company is currently not in compliance with the minimum Market Value of Listed Securities ("MVLS") requirement for continued listing on the NASDAQ Capital Market as set forth in NASDAQ Marketplace Rule 5550(b)(2), which requires the Company to have a minimum MVLS of $35 million for at least 30 consecutive business days. The Company has been given 180 calendar days, or until February 14, 2011, to regain compliance with Rule 5550(b)(2). In order to regain compliance with Rule 5550(b)(2), EntreMed's MVLS must close at $35 million or more for a minimum of 10 consecutive trading days. If, at any time prior to February 14, 2011, the MVLS is $35 million or more for 10 consecutive trading days, NASDAQ will provide written confirmation of compliance.  The NASDAQ notification letter has no immediate effect on the listing or trading of the Company's common stock on the NASDAQ Capital Market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

NASDAQ's Rule 5550(b), regarding continued listing requirements, requires that the companies listed on the NASDAQ Capital Market maintain a minimum stockholders' equity of $2.5 million, a MVLS of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.  If the Company does not regain compliance with Rule 5550(b)(2) by satisfying the MVLS requirement, or one of the other requirements of Rule 5550(b) by February 14, 2011, then NASDAQ will provide written notification to the Company that its securities will be subject to delisting from the NASDAQ Capital Market. At that time, the Company will be permitted to appeal NASDAQ's determination to a Listing Qualifications Panel.

The Company intends to actively monitor its MVLS and alternative continued listing requirements to regain compliance with NASDAQ listing standards. The Company may seek to raise additional capital in conjunction with clinical developments over the course of the remaining year to increase stockholders' equity.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including  the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize the royalty stream for any reason, including our inability to obtain the required third-party consents; declines in actual sales of Thalomid® resulting in reduced revenues; risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Contact:Ginny DunnAssociate DirectorCorporate Communications & Investor Relations 240-864-2643
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 9.2% over the next decade ... report analyzes the market estimates and forecasts for all the given ...
(Date:2/23/2017)... SAN DIEGO , Feb. 23, 2017 /PRNewswire/ ... MBVX), a clinical-stage oncology drug development company, announces ... Food and Drug Administration (FDA) authorizing the initiation ... a therapeutic treatment for pancreatic cancer. MVT-1075 ( ... antibody radioimmunotherapy (RIT). MabVax plans to initiate the ...
(Date:2/23/2017)... Orthopedic and cardiac devices will continue ... patterns lead to an increasing prevalence of musculoskeletal ... injuries, chronic back problems, heart valve replacement, and ... future of medical implants faces many uncertainties. ... more: - What types of medical implants ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... will return to the La Gorce Country Club in Miami Beach to host ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
(Date:2/23/2017)... IPSWICH, Mass. (PRWEB) , ... February 23, 2017 ... ... chosen as an approved content provider for the National Institute for Health ... care and social care-related organizations in the National Health Service (NHS) to search, ...
(Date:2/23/2017)... Denver, Colorado (PRWEB) , ... February 23, 2017 ... ... Dialog Magazine, an exciting, new, interactive publication where generations converge and explore the ... to expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, ...
(Date:2/23/2017)... ... 23, 2017 , ... Healthcare Research & Analytics® (HRA®) in ... against cancer, has produced a seminal study that asked cancer survivors and their ... in a webinar, Defining Compassionate Care Through the Voices of Patients and Advocates ...
Breaking Medicine News(10 mins):